Roche Holding AG (RHHBY)
OTCMKTS
· Delayed Price · Currency is USD
40.13
+0.28 (0.70%)
Sep 26, 2024, 3:59 PM EDT
Roche Holding AG Revenue
Roche Holding AG had revenue of 30.76B CHF in the half year ending June 30, 2024, a decrease of -9.27%. This brings the company's revenue in the last twelve months to 60.58B, down -3.12% year-over-year. In the year 2023, Roche Holding AG had annual revenue of 60.44B, down -8.16%.
Revenue (ttm)
60.58B CHF
Revenue Growth
-3.12%
P/S Ratio
0.48
Revenue / Employee
584.73K CHF
Employees
103,605
Market Cap
257.05B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
Dec 31, 2019 | 63.75B | 4.25B | 7.15% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.69B |
Ryman Healthcare Limited | 411.39M |
Verano Holdings Corp. | 920.97M |
Medexus Pharmaceuticals Inc. | 108.78M |
Roche Holding AG News
- 17 hours ago - Roche, Biogen kidney disease drug hits main goal in late-stage study - Seeking Alpha
- 22 hours ago - Positive Phase III Results for Genentech's Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis - Benzinga
- 22 hours ago - Positive phase III results for Roche's Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis - GlobeNewsWire
- 22 hours ago - Positive Phase III Results for Genentech's Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis - Business Wire
- 2 days ago - Roche: The Devil Is In The Details - Obesity Data Presentation Disappoints - Seeking Alpha
- 2 days ago - Roche narrows pipeline to 11 disease areas amidst weight loss push - WSJ - Seeking Alpha
- 2 days ago - Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses - GlobeNewsWire
- 3 days ago - WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche's role in pioneering cervical cancer solutions - GlobeNewsWire